Evidence map›Paper›PMID 41756886›Full record

ArticlebioRxiv : the preprint server for biology2026

The buried S2 apex of SARS-CoV-2 spike elicits an immunodominant germline-restricted public antibody response.

Suncheol Park, Jacob Mischka, Nisreen Okba, Anass Abbad, Meng Yuan, Komal Srivastava, Charles Gleason, Lubbertus C F Mulder, Jeffrey Copps, Katrina Saam and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Suncheol ParkDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-3910-6454
Jacob MischkaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nisreen OkbaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Anass AbbadDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Meng YuanDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-9754-4503
Komal SrivastavaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Charles GleasonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Lubbertus C F MulderDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jeffrey CoppsDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-4793-7258
Katrina SaamDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Sandhya BangaruDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-7994-4693
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-6469-2419
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-7153-3769

Funding

Understanding antibody responses and defining correlates of protection for endemic and pandemic coronavirus strainsP01AI172531 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ali Hassan Ellebedy, Viviana A Simon · 2023 to 2026
$12.5M
Novel B cell epitope discovery against human coronavirusesR01AI190286 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI IAN A WILSON · 2025 to 2026
$1.8M
NIAID NIH HHS P01 AI172531NIAID NIH HHS R01 AI190286
6 · The paper itself

Abstract

The continued mutational pressure on the SARS-CoV-2 S1 subunit underscores the need to target the conserved S2 region for pan-coronavirus vaccine development. A detailed molecular understanding of S2-directed immune responses is therefore essential. In this study, we identified the S2 apex as the most immunodominant epitope within the S2 subunit, eliciting robust antibody responses despite occlusion by S1, using electron-microscopy-based polyclonal epitope mapping (EMPEM) of plasma from infected and vaccinated individuals. Structure-guided sequence analysis with antibody databases revealed that antibodies targeting a poorly characterized S2 Apex-B site form a convergent public clonotype, which is predominantly derived from the IGHV3-30 germline with a 14-residue CDRH3 containing a G/S-G-S/N-Y motif. This clonotype is extensively expanded, accounting for up to 40% of total spike-reactive antibody sequence counts in individual vaccinated donors. This study elucidates the molecular basis the high-frequency elicitation of this non-neutralizing clonotype emphasizing that its immunodominance acts as a primary hurdle for universal coronavirus vaccines and underscore the need for precision antigen design to redirect immunity toward more potent neutralizing targets.

Indexed as

antibodyCOVID-19germlinepolyclonal responsepublic clonotypeS2-subunitSARS-CoV-2spike protein

Identifiers

PMID41756886
PMCPMC12934933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.